Cited by 326Cancer Immunotherapy and BiomarkersPituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

Faje, Alexander·2016·Pituitary

Open this paper in CoChat — free account

Abstract

Introduction Advances in immunotherapy have transformed the management of metastatic melanoma and generated encouraging results in the treatment of other malignancies. Autoimmune side effects from these agents, termed immune-related adverse events (IRAEs), are diverse and can include multiple endocrinopathies. Ipilimumab-induced hypophysitis (IH) is a recently recognized endocrine IRAE.Methods This review summarizes published data and experience from our center on the incidence, presentation and management, and proposed mechanisms for immunotherapy-related hypophysitis, with a focus on patients treated with ipilimumab (Ipi).Conclusion Hypophysitis occurs in a significant minority of patients treated with Ipi, in contrast to the relative rarity of idiopathic autoimmune hypophysitis or hypophysitis after treatment with other immunotherapies. Recently published cohorts have described the clinical presentation and management of IH and longitudinal outcomes in these patients. Additional studies with Ipi and other emerging agents have helped identify potential risk factors for the development of immunotherapy-related hypophysitis and possible underlying mechanisms for IH. Clarification of the mechanism(s) for IH may enhance our understanding of idiopathic autoimmune hypophysitis and could have potential therapeutic applications.

Integrity signals

Registry

Crossref · 10.1007/s11102-015-0671-4

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“treatment with anti-PD-1 or anti-PD-L1 agents is more common than hypophysitis and occurs in approximately 5–10 % of patients [20–28].”
Background
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y. J., Yuan, J. D., Kitano, S., Mu, Z., Rasalan, T. S., Adamow, M. J., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,105
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“pletion of Ipi therapy with or without temporary interruption may be safely tolerated in some patients with less severe cases of hypophysitis [16, 17, 54].”
Background
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,013
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 879
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 867
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M. K., Konto, C., & Wolchok, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 713
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 613
Autoimmune Hypophysitis
Caturegli, P., Newschaffer, C. J., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 612
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 589
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomão, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 545
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Faje, A. T., Sullivan, R. J., Lawrence, D. P., Tritos, N. A., Fadden, R. M., Klibanski, A., & Nachtigall, L. B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2306 · Cited by 490
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 418
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N. M., Butterfield, L. H., Tarhini, A. A., Leming, P. D., Puzanov, I. J., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 361
Emerging trends in the epidemiology of melanoma
Nikolaou, V. A., & Stratigos, A. J. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12492 · Cited by 357
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 327
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D. M., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Dillard, T. H., Yedinak, C. G., Alumkal, J. J., & Fleseriu, M. (2009) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 296
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Albarel, F., Gaudy‐Marqueste, C., Castinetti, F., Carré, T., Morange, I., Conte‐Devolx, B., Grob, J., & Brue, T. C. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0845 · Cited by 287
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Giacomo, A. M. D., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., Marasco, A., Rivoltini, L., Simeone, E., Nicoletti, S. V. L., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70324-8 · Cited by 285
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Min, L., Hodi, F. S., Giobbie‐Hurder, A., Ott, P. A., Luke, J. J., Donahue, H., Davis, M., Carroll, R. S., & Kaiser, U. B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2353 · Cited by 278
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, J. R., & Pardoll, D. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0078 · Cited by 195
Human IgG subclass pattern of inducing complement‐mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration
Michaelsen, T. E., Garred, P., & Aase, A. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210103 · Cited by 177
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 166
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
Laurent, S., Queirolo, P., Boero, S., Salvi, S., Piccioli, P., Boccardo, S., Minghelli, S., Morabito, A., Fontana, V., Pietra, G., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-108 · Cited by 163
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells
Pistillo, M. P. (2002) · Blood · doi:10.1182/blood-2002-06-1668 · Cited by 127
Lymphocytic hypophysitis. A review of 145 cases.
Beressi, N., Beressi, J.-P., Cohen, R., & Modigliani, E. (1999) · PubMed · Cited by 124
64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
Higashikawa, K., Yagi, K., Watanabe, K., Kamino, S., Ueda, M., Hiromura, M., & Enomoto, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109866 · Cited by 118
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
The IgG Subclass Pattern of Complement Activation Depends on Epitope Density and Antibody and Complement Concentration
Garred, P., Michaelsen, T. E., & Aase, A. (1989) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1989.tb01225.x · Cited by 103
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
Johnson, D. B., Friedman, D. L., Berry, E., Decker, I., Ye, F., Zhao, S., Morgans, A. K., Puzanov, I., Sosman, J. A., & Lovly, C. M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0217 · Cited by 101
Costimulatory Markers in Muscle of Patients with Idiopathic Inflammatory Myopathies and in Cultured Muscle Cells
Nagaraju, K., Raben, N., Villalba, M. L., Danning, C. L., Loeffler, L., Lee, E. Y., Tresser, N. J., Abati, A. D., Fetsch, P. A., & Plötz, P. H. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4743 · Cited by 99
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Mao, H., Zhang, L., Yang, Y., Zuo, W., Bi, Y., Gao, W., Deng, B., Sun, J., Shao, Q., & Qu, X. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793605811 · Cited by 97
Immune-priming of the Tumor Microenvironment by Radiotherapy
Shahabi, V., Postow, M. A., Tuck, D. P., & Wolchok, J. D. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182868ec8 · Cited by 86
CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
Shah, K. V., Chien, A. J., Yee, C., & Moon, R. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.170 · Cited by 84
The CTLA-4 gene is expressed in placental fibroblasts
Kaufman, K. A. (1999) · Molecular Human Reproduction · doi:10.1093/molehr/5.1.84 · Cited by 83
ATM, CTLA4, MNDA, andHEM1in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia
Joshi, A. D., Hegde, G. V., Dickinson, J. D., Mittal, A. K., Lynch, J. C., Eudy, J. D., Armitage, J. O., Bierman, P. J., Bociek, R. G., Devetten, M. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0283 · Cited by 75
Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
Nallapaneni, N. N., Mourya, R., Bhatt, V. R., Malhotra, S., Ganti, A. K., & Tendulkar, K. K. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0105 · Cited by 74
Autoimmune Hypophysitis of SJL Mice: Clinical Insights from a New Animal Model
Tzou, S., Lupi, I., Landek‐Salgado, M. A., Gutenberg, A., Tzou, Y.-M., Kimura, H. J., Pinna, G., Rose, N. R., & Caturegli, P. (2008) · Endocrinology · doi:10.1210/en.2007-1692 · Cited by 59
Hypophysitis
Fukuoka, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.011 · Cited by 50
Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab
van der Hiel, B., Blank, C. U., Haanen, J. B. A. G., & Stokkel, M. P. M. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182639765 · Cited by 45
PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic disease
Krönig, H., Falchner, K. J., Odendahl, M., Brackertz, B., Conrad, H., Muck, D., Hein, R., Blank, C. U., Peschel, C., Haller, B., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26272 · Cited by 44
CTLA‐4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis
Laurent, S., Palmisano, G. L., Martelli, A. M., Kato, T., Tazzari, P. L., Pierri, I., Clavio, M., Dozin, B., Balbi, G., Megna, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06472.x · Cited by 41
T regulatory cells distinguish two types of primary hypophysitis
Mirocha, S., Elagin, R. B., Salamat, S. M., & Jaume, J. C. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03828.x · Cited by 40
CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer
Antczak, A. J., Pastuszak‐Lewandoska, D., Górski, P., Domańska, D., Migdalska‐Sęk, M., Czarnecka, K. H., Nawrot, E., Kordiak, J., & Brzeziańska‐Lasota, E. (2013) · BioMed Research International · doi:10.1155/2013/576486 · Cited by 38
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin
Ridruejo, E., Christensen, A. F., & Mandό, O. G. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200606000-00019 · Cited by 35
Reversible hypopituitarism after interferonalfa therapy
Sakane, N., Yoshida, T., Yoshioka, K., Umekawa, T., Kondo, M., & Shimatsu, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90950-8 · Cited by 33
Interferon-induced hypopituitarism
Concha, L. B., Carlson, H. E., Heimann, A., Lake‐Bakaar, G., & Paal, A. F. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01323-2 · Cited by 32
Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage
Tsai, A. F., Kaufman, K. A., Walker, M. A., Karrison, T. G., Odem, R. R., Barnes, R. B., Scott, J. R., Schreiber, J. R., Stephenson, M. D., & Ober, C. (1998) · Journal of Reproductive Immunology · doi:10.1016/s0165-0378(98)00073-4 · Cited by 31
Granulomatous Adenohypophysitis after Interferon and Ribavirin Therapy
Tebben, P. J., Atkinson, J. L. D., Scheithauer, B. W., & Erickson, D. Z. (2007) · Endocrine Practice · doi:10.4158/ep.13.2.169 · Cited by 26
CTLA-4 polymorphism 49A–G is associated with placental abruption and preeclampsia in Finnish women
Jääskeläinen, E., Toivonen, S., Keski‐Nisula, L., Paattiniemi, E.-L., Helisalmi, S., Punnonen, K. R. A., & Heinonen, S. T. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.034 · Cited by 25
Panhypopituitarism in association with interferon-alpha treatment.
Chan, J. C. N., & Cockram, C. S. (2004) · PubMed · Cited by 19
Anticytotoxic T-Lymphocyte Antigen-4 Induced Autoimmune Hypophysitis: A Case Report and Literature Review
Majchel, D., & Korytkowski, M. T. (2015) · Case Reports in Endocrinology · doi:10.1155/2015/570293 · Cited by 9
Expression and function of CTLA4 in melanoma.
Seliger, B., Maio, M., Cuaia, O., & Calabrò, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e20040 · Cited by 7
Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone
Chen, B., Phillips, J., Greenbaum, M., Klitzing, D., Cardarelli, P. M., & Korman, A. J. (2007) · Cancer Research · Cited by 5
Abstract B23: Autoimmune hypophysitis is a marker of favorable outcome during treatment of melanoma with ipilimumab
Eatrides, J. M., Weber, J. S., Egan, K. M., Acierno, M., Schell, M. J., Lillienfeld, H., & Creelan, B. (2015) · Cancer Research · doi:10.1158/1538-7445.mel2014-b23 · Cited by 4

Sorted by citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685

See all 326

Authors: Faje, A.
Affiliations: Harvard University (US)
Corresponding author: Faje, Alexander
ORCID: Faje, Alexander
Venue: Pituitary
Publisher: Springer Science and Business Media LLC
Published: 2015-07-18
Volume: 19
Issue: 1
Pages: 82-92
ISSN: 1386-341X (ISSN-L)
1573-7403
DOI: 10.1007/s11102-015-0671-4
OpenAlex: W1185432402
Cited by: 326
References: 88
Citations by year: 2026: 12 · 2025: 25 · 2024: 16 · 2023: 29 · 2022: 32 · 2021: 37 · 2020: 49 · 2019: 36 · 2018: 41 · 2017: 31 · 2016: 18
FWCI: 3.22
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Pituitary (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords: immune-related adverse events, immunotherapy, autoimmune hypophysitis, metastatic melanoma, endocrine adverse events, risk factors
MeSH terms: Hypophysitis, Ipilimumab, Antibodies, Monoclonal, Humans, Immunotherapy, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks